Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised

Executive Summary

Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests
Advertisement

Related Content

Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Boniva Labeling Reflects Class Osteonecrosis, Musculoskeletal Pain Risk
Advertisement
UsernamePublicRestriction

Register

PS046754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel